Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
Study for Subjects with Age-Related Macular Degeneration using investigational drug Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily.
Sponsor: Ohr Pharmaceutical, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ6799
U.S. Govt. ID: NCT02727881
Contact: Maribel Rodriguez: 212-305-1407 / mr3208@cumc.columbia.edu
Additional Study Information: Macular degeneration is a progressive eye disease that damages the macula. The macula is the part of the eye that is responsible for central vision, which is needed to perform straight-ahead activities, such as reading, driving, or watching TV. This research is being conducted to learn about the safety and efficacy (how effectively the study drug works) of a drug (an eye drop) called Squalamine Lactate Ophthalmic Solution, 0.2% given in conjunction with an injection into the eye of Lucentis which is the standard-of-care for the treatment of wet-AMD.
This study is closed
Investigator
Tongalp Tezel, MD
Do You Qualify?
Have you been diagnosed with AMD (Age related Macular Degeneration)? Yes No
Are you 50 years of age or over? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Maribel Rodriguez
mr3208@cumc.columbia.edu
212-305-1407